| Methods for high-throughput drug combination screening and synergy scoring L He, E Kulesskiy, J Saarela, L Turunen, K Wennerberg, T Aittokallio, ... Cancer systems biology: methods and protocols, 351-398, 2018 | 193 | 2018 |
| Prediction of drug combination effects with a minimal set of experiments A Ianevski, AK Giri, P Gautam, A Kononov, S Potdar, J Saarela, ... Nature machine intelligence 1 (12), 568-577, 2019 | 127 | 2019 |
| APECED‐causing mutations in AIRE reveal the functional domains of the protein M Halonen, H Kangas, T Rüppell, T Ilmarinen, J Ollila, M Kolmer, ... Human mutation 23 (3), 245-257, 2004 | 124 | 2004 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 92 | 2022 |
| HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017 | 91 | 2017 |
| Breeze: an integrated quality control and data analysis application for high-throughput drug screening S Potdar, A Ianevski, JP Mpindi, D Bychkov, C Fiere, P Ianevski, B Yadav, ... Bioinformatics 36 (11), 3602-3604, 2020 | 89 | 2020 |
| Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity J Bruun, K Kryeziu, PW Eide, SH Moosavi, IA Eilertsen, J Langerud, ... Clinical Cancer Research 26 (15), 4107-4119, 2020 | 76 | 2020 |
| Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations J Saarela, M Laine, C Oinonen, C Schantz, A Jalanko, J Rouvinen, ... Human molecular genetics 10 (9), 983-995, 2001 | 66 | 2001 |
| Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)–distinct characteristics in neurons A Lyly, C Von Schantz, T Salonen, O Kopra, J Saarela, M Jauhiainen, ... BMC cell biology 8, 1-14, 2007 | 53 | 2007 |
| Activation and oligomerization of aspartylglucosaminidase J Saarela, M Laine, C Oinonen, A Jalanko, J Rouvinen, L Peltonen, ... Journal of Biological Chemistry 273 (39), 25320-25328, 1998 | 52 | 1998 |
| Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins D Bulanova, A Ianevski, A Bugai, Y Akimov, S Kuivanen, H Paavilainen, ... Viruses 9 (10), 271, 2017 | 48 | 2017 |
| Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner A Kreutzman, B Colom-Fernández, AM Jiménez, M Ilander, ... Clinical Cancer Research 23 (21), 6697-6707, 2017 | 45 | 2017 |
| The patatin-like lipase family in Gallus gallus J Saarela, G Jung, M Hermann, J Nimpf, WJ Schneider BMC genomics 9, 1-15, 2008 | 44 | 2008 |
| Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data JP Mpindi, P Swapnil, B Dmitrii, S Jani, K Saeed, K Wennerberg, ... Bioinformatics 31 (23), 3815-3821, 2015 | 43 | 2015 |
| Autoproteolytic activation of human aspartylglucosaminidase J Saarela, C Oinonen, A Jalanko, J Rouvinen, L Peltonen Biochemical journal 378 (2), 363-371, 2004 | 43 | 2004 |
| Identification of an aspartylglucosaminidase-like protein in the venom of the parasitic wasp Asobara tabida (Hymenoptera: Braconidae) SJM Moreau, A Cherqui, G Doury, F Dubois, Y Fourdrain, L Sabatier, ... Insect Biochemistry and Molecular Biology 34 (5), 485-492, 2004 | 42 | 2004 |
| Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer J Tang, P Gautam, A Gupta, L He, S Timonen, Y Akimov, W Wang, ... NPJ systems biology and applications 5 (1), 20, 2019 | 31 | 2019 |
| Precision cancer medicine in the acoustic dispensing era: ex vivo primary cell drug sensitivity testing E Kulesskiy, J Saarela, L Turunen, K Wennerberg Journal of laboratory automation 21 (1), 27-36, 2016 | 31 | 2016 |
| High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 in vitro L Torrente, G Maan, A Oumkaltoum Rezig, J Quinn, A Jackson, A Grilli, ... Biomolecules 10 (10), 1365, 2020 | 30 | 2020 |
| Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma K Hansson, K Radke, K Aaltonen, J Saarela, A Mañas, J Sjölund, ... Science translational medicine 12 (562), eaba4434, 2020 | 26 | 2020 |
